Lenacapavir: The Future of HIV Treatment & PrEP — But What About India?

Lenacapavir-injection

If you follow global HIV breakthroughs, you’ve surely heard about Lenacapavir — a revolutionary twice-a-year injection that’s changing how we think about HIV prevention (PrEP) and treatment (ART).

Approved under the brand names Sunlenca® (for treatment) and Yeztugo® (for PrEP), Lenacapavir is hailed for its convenience: just one injection every six months instead of daily pills.

How does Lenacapavir help?

  • For people with drug-resistant HIV, Sunlenca® offers fresh hope.
  • For HIV-negative people at risk, Yeztugo® promises long-lasting protection.

Side effects? Mostly mild: injection site pain, headache, nausea.

The catch? It’s not available in India yet — and costs a whopping $28,000–$30,000 USD per year (₹23–25 lakh). Realistically, it may take 1.5–2 years (or more) to arrive and become affordable here.

What’s your best option until then?

👉 Daily oral PrEP is proven, safe, and costs only ₹1,000–₹2,500 per month.

At DrSafeHands, we make PrEP easy: discreet counseling, expert doctors, and home delivery.

💡 Why wait? Protect yourself today, not years later.


Who Can Use Lenacapavir?

Lenacapavir is approved for use in adults with HIV-1 infection who are heavily treatment-experienced and whose virus is resistant to multiple classes of HIV medications. Your HIV specialist at DrSafeHands will assess your eligibility based on your medical history and viral resistance profile.